Blog
Published December 7, 2023
Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both academics and the life sciences industry, including manufacturers, regulatory leaders and health economists, to consider the latest challenges and opportunities being addressed by health economics and outcomes research. Topics included Joint Clinical Assessments (JCAs), access to innovative therapies, environmental…
Read Now
Webinars
Available On Demand
In Part 1 of this webinar series, The Path to Launch, we discussed various pathways and innovative programs to accelerate product launch in China. However, launching a product is only half of the battle. Ensuring optimal access to deliver the treatment to more patients is also critical for commercial success.Join Trinity Life Sciences’ APAC experts for Part 2 as they decode recent key pricing and access dynamics in the China pharmaceutical market and explore what strategies and levers are available to…
Watch Now
Blog
Published July 27, 2023
Trinity’s Take
Recent guidance for the Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program released by CMS retains all major provisions of the program as written in the IRA
The guidance details negotiation methodology, including that CMS will not leverage any type of formulaic mechanism to determine the offered Maximum Fair Price (MFP) but rather leverage the nine negotiation factors published in the IRA as a platform for negotiation
Although CMS will offer a public explanation for each final…
Read Now
Blog
Published July 17, 2023
This year Trinity team members at ISPOR 2023 attended several symposia and presentations on the use of Artificial Intelligence (AI) to support biopharma evidence generation. Among many industry trends, experts anticipate that AI and machine learning will increasingly be leveraged to identify optimal patient populations and expedite the path toward personalized medicine.
Pioneering New Frontiers in Health Economics and Market Access: The transformative power of AI, ML and advanced data analytics
This symposium focused on the role of innovative technologies…
Read Now
Blog
Published July 10, 2023
While attending the ISPOR US 2023 conference in Boston this year, Trinity team members had the opportunity to connect with industry colleagues, present original research, and participate in research panels and discussions regarding key industry trends. One top of mind industry topic for many attendees and presenters was the recent enactment of the 2022 Inflation Reduction Act (IRA). Throughout the conference, several key health policy implications stemming from the IRA for the biopharma industry were explored.
Long-term Pricing Pressure for…
Read Now
Blog
Published June 21, 2023
Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez, MD, MS, MBA, all experts in the field of Digital Therapeutics (DTx), about the role of evidence development in the approval of DTx to date, and what evidence development requirements could look like in the next five years.
Past…
Read Now
Webinars
Available On Demand
The unprecedented availability of rich RWE data sources gives HEOR, Value and Access and Medical leaders the opportunity to be more intentional than ever before. High-quality, compelling evidence is now a necessity, not just for high-value therapies playing in the rare disease space—but also more broadly, to show reduced unmet needs, health care resource utilization (HCRU) and cost offsets.
Deep experience using industry-leading data sources, tech-enabled methodologies and therapeutic expertise allow Trinity experts to choose the right data for each…
Watch Now
Blog
Published June 16, 2023
Last month, Trinity attended the ISPOR 2023 conference in Boston. The main theme of the conference was “Impacting Innovation, Value and Healthcare Decision Making”, which facilitated unique discussions and workshops across different stakeholders in the life sciences, including manufacturers, regulatory leaders and health economists. Topics included discussions on the role of artificial intelligence (AI) in HEOR, innovation in evidence generation, the latest trends in health policy and a myriad of others.
A highlight for Trinity Life Sciences was presenting 12…
Read Now
Webinars
Available On Demand
Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success. In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window. The life sciences industry now seeks to understand how the vision for commercial success will evolve while in parallel navigating new artificial intelligence (AI) and other general-purpose technologies (GPTs) technologies…
Watch Now
Blog
Published April 21, 2023
Executive Summary
Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success.
In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window.
Trinity’s Take
These events usher in a new era for the life sciences industry, necessitating new thinking around development and commercialization strategy.
Historic reliance on the U.S. market…
Read Now
